Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in monoclonal gammopathy of undetermined significance in western Paraná
RBR-9p6x9yhPhase 2Recruiting
- Sponsor
- Unioeste
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in monoclonal gammopathy of undetermined significance (MGUS), sponsored by Unioeste. Primary endpoint: Change in monoclonal protein concentration. Started Aug 2024; status: recruiting.
02
Drugs
metformin
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)
Beyond the preview
Go deeper on RBR-9p6x9yh.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9p6x9yh.